Gaxos Health Forms Medical Advisory Board to Support Launch of AI-powered Health and Wellness Solution
- None.
- None.
Insights
The formation of a medical advisory board by Gaxos Health, particularly with Dr. Nate Lebowitz as the Chairman, signifies a strategic move towards enhancing product development within the health and wellness sector. Dr. Lebowitz's extensive background in cardiology and his involvement in clinical trials and research publications underscore a commitment to evidence-based product development. This initiative could potentially lead to innovative solutions that address cardiometabolic disorders and other health issues, which may improve patient outcomes and, consequently, increase the company's market share in the health tech industry.
From an investment perspective, the appointment of a recognized medical expert to the advisory board can be viewed as a positive indicator of the company's dedication to quality and efficacy in its product offerings. This could translate into increased investor confidence and possibly attract further investment, fostering growth and expanding the company's foothold in the competitive health technology market.
Considering the broader market implications, the establishment of a medical advisory board by Gaxos Health, with a focus on cardiology, aligns with the growing demand for specialized health and wellness technologies. The integration of AI within healthcare is a burgeoning field and Gaxos's initiative to leverage expert medical advice could differentiate their products, offering a competitive edge. By focusing on prevalent issues such as obesity and cardiometabolic disorders, Gaxos Health may capture a significant segment of the market that is increasingly concerned with these health challenges.
Moreover, a medical advisory board can provide strategic insights into regulatory compliance and market needs, which are crucial for the successful launch and adoption of new health technologies. The anticipation of such advancements may lead to speculative trading, influencing the company's stock performance in the short term.
Dr. Lebowitz's expertise in vascular biology and cardiometabolic disorders suggests that Gaxos Health may be focusing on developing AI applications targeted at cardiovascular diseases, which remain the leading cause of death globally. The potential for AI to revolutionize the management and treatment of these diseases could be substantial, offering predictive analytics for patient risk assessment, personalized treatment plans and improved diagnostic tools.
The long-term success of Gaxos Health's endeavors will largely depend on the company's ability to translate the advisory board's clinical insights into commercially viable products. It will also hinge on navigating the stringent regulatory landscape governing health technology, a process that could be streamlined with the guidance of experienced medical professionals.
Roseland, NJ, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that its health and wellness division, Gaxos Health, has formed a medical advisory board for providing invaluable insight into product development and creating strategic opportunities. The Company has appointed Dr. Nate Lebowitz, M.D. as the Chairman of the Advisory Board.
“The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI. “An advisory board of experts in medicine will be instrumental in guiding us through the process of offering the best product and advancing our mission of creating value for shareholders.”
Dr. Nate Lebowitz, MD, is a leading cardiologist at Hackensack University Medical Center in New Jersey. He is an attending cardiologist at Hackensack University Medical Center’s Heart and Vascular Hospital where he is director of lipids and preventive cardiology. He is also an attending cardiologist at Englewood Hospital and Medical Center. Dr. Lebowitz received his MD from Cornell University Medical College (now Weill-Cornell Medical College) in New York. He completed his residency in internal medicine at Yale – New Haven Hospital in New Haven, Connecticut, and a fellowship in cardiology at the New York Hospital – Cornell Medical Center in New York, New York. He is board certified in cardiology.
Dr Lebowitz is a fellow of the American College of Cardiology. He is a diplomate of the American Society of Nuclear Cardiology (ASNC), and a member of the National Lipid Association and the American Society of Nuclear Cardiology He is also a founding member of the Society for the Advancement of Blood Management and co-founder of the ASNC New Jersey Working Group.
Dr Lebowitz’s clinical and research interests include plaque morphology in vascular biology, genetic dyslipidemias, obesity, nutrition and cardiometabolic disorders. He has authored or coauthored articles published in peer-reviewed journals such as the Journal of the American College of Cardiology and the Annals of Thoracic Surgery. He is principal investigator in multicenter clinical trials.
“We welcome Dr. Lebowitz to the advisory board as his experience and talents will be invaluable to the creation of our solution,” Vadim Mats added. “We look forward to leveraging his insights and expertise.”
About Gaxos.ai Inc.
Gaxos.AI isn't just developing applications; it's redefining the human-AI relationship. Our offerings span health and wellness as well as gaming. We're committed to addressing health, longevity, and entertainment, through AI solutions.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
Gaxos.ai Inc. Company Contact
Investor Relations
E:ir@gaxos.ai
T: 1-888-319-2499
FAQ
Who is leading the medical advisory board at Gaxos Health?
What is the role of Dr. Nate Lebowitz, M.D. in the advisory board?
Where is Dr. Nate Lebowitz, M.D. currently practicing?
What are Dr. Lebowitz's clinical and research interests?
What are Dr. Lebowitz's certifications and memberships?
